---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-045465"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2023-08-30T23:59:59+00:00"
generated_at: "2026-06-11T01:54:46.192554+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nasdaq panel grants Heart Test Labs continued listing with compliance deadlines

## Summary
- Hearing Panel granted continued listing on Nasdaq Capital Market subject to conditions.
- Company must demonstrate compliance with Equity Rule (minimum stockholders' equity) by Nov 21, 2023.
- Company has until Jan 29, 2024 to meet the $1 minimum bid price requirement.
- Previously received delist notice on June 20, 2023 for non-compliance with Equity Rule; appeal filed June 27.
- Also received bid price deficiency notice on Aug 1, 2023; separate condition for bid price compliance.

## SEC filing metadata
- accession: 0000950170-23-045465
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2023-08-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017023045465/0000950170-23-045465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017023045465/hscs-20230828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-045465
- JSON: https://secwatch.observer/filing/0000950170-23-045465.json
- Plain text: https://secwatch.observer/filing/0000950170-23-045465.txt

## Key facts
- Listing & Compliance Notices
  HeartSciences Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: August 1, 2023, the Staff notified the Company that the bid price of its common stock failed to close above the minimum $1 requirement for the past 30 trading days, pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Company attended an August 17, 2023, hearing before the Panel and requested the continued listing of its securities on the Nasdaq Capital Market pending its return to compliance with the Equity Rule and the Bid Price Rule. On August 28, 2023, the Company received a decision from the Panel granting the Company’s request for continued listing on the Nasdaq Capital
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000095017023045465/0000950170-23-045465-index.htm
- Listing & Compliance Notices
  HeartSciences Inc. received a nasdaq hearing update notice regarding stockholders equity (rules 5250(b)(1)).
  - Exchange: nasdaq
  - Notice: hearing update
  - Deficiency: stockholders equity
  - Rules: 5250(b)(1)
  source text: August 28, 2023, the Company received a decision from the Panel granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with the Equity Rule on or before November 21, 2023, and certain other conditions. In addition, The Company has until January 29, 2024, to demonstrate compliance with the minimum $1 bid price requirement pursuant to the Bid Price Rule. Statements contained herein relating to the Company or its management’s intentions, hopes, beliefs, expectations or predictions of the future, including, but not limited
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000095017023045465/0000950170-23-045465-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.